nor-Binaltorphimine dihydrochloride: Benchmarking the Selective κ-Opioid Receptor Antagonist

Executive Summary: nor-Binaltorphimine dihydrochloride (SKU B6269) is a potent and selective κ-opioid receptor (KOR) antagonist developed for research use only (APExBIO, product page). Its chemical structure (C₄₀H₄₃N₃O₆·2HCl, MW 734.72) provides high affinity and specificity for KORs, inhibiting their activity in a dose-dependent manner (Huo et al., 2023). The compound is used to dissect opioid receptor-mediated signal transduction and to study pain and addiction circuits under various physiological and pathological conditions. nor-Binaltorphimine dihydrochloride demonstrates low solubility in DMSO (<18.37 mg/mL), requires -20°C storage, and is not recommended for long-term solution storage. It is supplied at ≥98% purity, and shipped on blue ice for stability (APExBIO, 2024).

Biological Rationale

Kappa opioid receptors (KORs) are G protein-coupled receptors (GPCRs) found throughout the central and peripheral nervous systems. They regulate pain perception, stress responses, and addiction pathways (Huo et al., 2023). Selective antagonists, such as nor-Binaltorphimine dihydrochloride, enable precise interrogation of KOR function by blocking receptor-mediated signaling without significant off-target effects. This specificity is critical for studying the distinct contributions of KORs to pain modulation, mechanical allodynia, and neurocircuitry underlying dependence and affective disorders. In preclinical models, modulation of KORs alters the duration and laterality of mechanical allodynia, corroborating their central role in pain and reward-related circuitry (Huo et al., 2023).

Mechanism of Action of nor-Binaltorphimine dihydrochloride

nor-Binaltorphimine dihydrochloride acts as a highly selective, long-acting antagonist at KORs. Upon administration, it binds to the orthosteric site of the KOR, competitively inhibiting endogenous ligands such as dynorphins. This blockade suppresses KOR-mediated G_i/o protein signaling, preventing the typical downstream effects such as inhibition of adenylyl cyclase, reduced cAMP levels, and decreased neuronal excitability. The selectivity profile ensures minimal impact on mu (μ) or delta (δ) opioid receptors, as confirmed by radioligand binding and functional assays (Huo et al., 2023). The compound is particularly valued for studies dissecting the inhibitory "Hypothalamic Dyn/spinal KOR" axis that modulates pain transmission in the spinal dorsal horn (SDH). For a mechanistic deep dive, see "nor-Binaltorphimine Dihydrochloride: Unraveling κ-Opioid ...", which this article extends by providing updated circuit-level evidence and product-specific parameters.

Evidence & Benchmarks

• nor-Binaltorphimine dihydrochloride selectively blocks KOR activity in spinal dorsal horn neurons, prolonging bilateral mechanical allodynia in murine models (Huo et al., 2023).
• Administration (in vivo, 10 mg/kg, i.p.) results in persistent KOR blockade for >24 hours under physiological conditions (Huo et al., 2023).
• KOR antagonism by nor-Binaltorphimine dihydrochloride suppresses the inhibitory hypothalamic dynorphinergic pathway, impacting pain gating and affective behaviors (Huo et al., 2023).
• nor-Binaltorphimine dihydrochloride demonstrates negligible cross-reactivity with μ- or δ-opioid receptors at concentrations up to 1 µM in receptor binding assays (Huo et al., 2023).
• Solution stability is maintained for 1–2 days at 4°C in DMSO; longer storage results in degradation and loss of potency (APExBIO, product page).

This article clarifies and updates the translational research context discussed in "Unlocking the Power of Selective κ-Opioid Receptor Antago..." by integrating the most recent circuit-level findings and validated product specifications.

Applications, Limits & Misconceptions

nor-Binaltorphimine dihydrochloride is widely used in preclinical research to interrogate KOR-dependent mechanisms in pain, affect, and addiction. Its main applications include:

• Dissecting pain circuits: Used to block KORs in neural pathways controlling mechanical allodynia and pain modulation (Huo et al., 2023).
• Addiction and dependence studies: Enables evaluation of KOR antagonism in models of opioid withdrawal, stress-induced relapse, and negative affective states.
• Opioid receptor pharmacology: Serves as a negative control in receptor antagonist assays, confirming the specificity of KOR-targeted interventions.
• Cell signaling research: Facilitates mapping of opioid receptor-mediated signal transduction in isolated neurons or recombinant systems.

For practical workflow scenarios and troubleshooting, see "Scenario-Driven Solutions with nor-Binaltorphimine dihydr...", which this article enhances by offering updated storage and stability guidelines.

Common Pitfalls or Misconceptions

• Not a pan-opioid antagonist: nor-Binaltorphimine dihydrochloride does not block μ- or δ-opioid receptors at standard research concentrations.
• Long-term solution storage is unsuitable: Solutions degrade rapidly at ambient temperature or after several days, even at 4°C.
• Not for clinical or diagnostic use: The compound is intended for research purposes only and lacks regulatory approval for therapeutic use (APExBIO).
• Ineffective in non-KOR-mediated pathways: It does not inhibit pain or addiction behaviors independent of KOR signaling.
• Stability limitations in aqueous buffers: Solubility and stability are optimized in DMSO, not in water-based solvents.

Workflow Integration & Parameters

For optimal results in opioid receptor antagonist assays, nor-Binaltorphimine dihydrochloride should be dissolved in DMSO at concentrations up to 18.37 mg/mL. Solutions should be prepared fresh or used within 48 hours if stored at 4°C. Store the solid compound at -20°C. Shipments from APExBIO are on blue ice to ensure compound integrity. For in vivo studies, dosing regimens typically range from 1–10 mg/kg, with effects persisting for 24 hours or more depending on the species and administration route (Huo et al., 2023). In cell-based assays, effective concentrations are generally ≤1 μM. For more guidance on integrating this compound into receptor signaling studies, the nor-Binaltorphimine dihydrochloride product page offers additional vendor protocols and safety data sheets.

This article advances the protocol precision discussed in "nor-Binaltorphimine Dihydrochloride: Advancing Selective ..." by detailing validated storage and preparation parameters.

Conclusion & Outlook

nor-Binaltorphimine dihydrochloride, supplied by APExBIO, is a validated, robust, and highly selective tool for KOR research. Its effectiveness in opioid receptor signaling studies, pain modulation research, and addiction models is underpinned by peer-reviewed evidence and stringent product quality controls. Continued advances in circuit-specific pain and addiction research highlight its value and ensure its ongoing relevance in translational pharmacology. For a comprehensive overview and ordering information, refer to the official product page.